Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | synuclein, alpha (non A4 component of amyloid precursor) | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed), eta | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | dna polymerase eta | 0.0054 | 0.6288 | 0.5783 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1197 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0054 | 0.6288 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1197 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1197 | 0.1904 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.1197 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 0.6288 | 0.5783 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1197 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1197 | 0.1904 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1197 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0054 | 0.6288 | 0.5783 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1197 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1197 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0038 | 0.3628 | 0.4775 |
Echinococcus granulosus | dna polymerase eta | 0.0054 | 0.6288 | 0.5783 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0038 | 0.3628 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0054 | 0.6288 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1197 | 0.1904 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1197 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Schistosoma mansoni | DNA polymerase eta | 0.0054 | 0.6288 | 0.5783 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0054 | 0.6288 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.1197 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1197 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0038 | 0.3628 | 0.4775 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 3.9811 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 8.9125 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of L3MBTL1. (Class of assay: confirmatory) [Related pubchem assays: 485292 (Probe Development Summary for Inhibitors of L3MBTL1)] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.